Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.56 |
| ▸ | MAOA | P21397 | 6/20 | 0.56 |
| ▸ | F10 | P00742 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | CALML3 | P27482 | 1/20 | 0.45 |
| ▸ | SDHA | P31040 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18410586 | 1.00 | MAOB (0.56) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL20296415 | 0.98 | MAOB (0.54) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL18408806 | 0.98 | MAOB (0.54) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL20296259 | 0.88 | GRM2 (0.42) | MAOBMAOAF10LMNACALML3 | |
| SCHEMBL18410545 | 0.88 | GRM2 (0.42) | MAOBMAOAF10LMNACALML3 | |
| SCHEMBL12317752 | 0.87 | MAOB (0.64) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL2464074 | 0.87 | MAOB (0.64) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL18410541 | 0.87 | MAOB (0.58) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL20296094 | 0.87 | MAOB (0.58) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL20295918 | 0.84 | MAOB (0.47) | MAOBMAOAF10LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964949-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-3932917-A2 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | The Global Alliance for TB Drug Development, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20200148651-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10550092-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180179168-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964949-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THPO, TBCD, OXA1L | MAOB 1541/4885MAOA 2234/4885F10 4810/4885 |
| US-20180179168-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THPO, TBCD, OXA1L | MAOB 1541/4885MAOA 2234/4885F10 4810/4885 |
| US-20200148651-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THPO, TBCD, OXA1L | MAOB 1541/4885MAOA 2234/4885F10 4810/4885 |
| US-10550092-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THPO, TBCD, OXA1L | MAOB 1541/4885MAOA 2234/4885F10 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.